Form 4: Lantern Pharma Director Granted Stock Options

Lantern Pharma Inc. Director Maria-Luisa Maccecchini was granted 46,152 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Summary

• Maria-Luisa Maccecchini, a Director of Lantern Pharma Inc. (LTRN), acquired 46,152 stock options on January 9, 2026.
• The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• A grant of 25,000 stock options will vest in equal monthly increments over a 24-month period, commencing February 9, 2026.
• An additional grant of 21,152 stock options will vest in equal monthly increments over a 12-month period, also commencing February 9, 2026.
• All granted options have an exercise price of $3.49 per share and an expiration date of January 8, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that generally aligns the director's interests with shareholders, which is mildly positive for corporate governance and long-term strategy. It does not, however, indicate any immediate operational or financial performance changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options are granted under an existing and approved stock incentive plan, indicating a structured approach to executive compensation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting and expiration schedules of the granted options.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across many public companies, to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a standard practice, comparable to compensation structures observed in other publicly traded biotech and pharma companies.
• Vesting schedules of 12 and 24 months are typical for such grants, designed to encourage long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Maria-Luisa Maccecchini, a Director of Lantern Pharma Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's management.

Stakeholder Impact

• Shareholders: The grant aims to align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: While this specific grant is for a director, it reflects the company's broader use of equity incentive plans, which can also impact employee motivation and retention.

Next Steps

• The granted stock options will begin vesting in equal monthly increments starting February 9, 2026, over periods of 12 and 24 months.

Key Dates

Keywords

Lantern Pharma, LTRN, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan